| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Cristina Sampaio | Q28359585 |
| Tiago Mestre | Q28359619 | ||
| Miguel M. Coelho | Q55232782 | ||
| Joaquim Ferreira | Q55232786 | ||
| P2093 | author name string | Mário Rosa | |
| P2860 | cites work | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Trinucleotide repeat length and progression of illness in Huntington's disease | Q33596210 | ||
| Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study | Q33994217 | ||
| Huntington's disease: present treatments and future therapeutic modalities | Q34312421 | ||
| Detection of Huntington's disease decades before diagnosis: the Predict-HD study | Q36941187 | ||
| Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial | Q39118783 | ||
| Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. | Q40462605 | ||
| A controlled trial of idebenone in Huntington's disease | Q40929165 | ||
| A controlled clinical trial of baclofen as protective therapy in early Huntington's disease | Q41265980 | ||
| MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment | Q43940983 | ||
| Minocycline for Huntington's disease: an open label study | Q44357409 | ||
| Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. | Q44504149 | ||
| Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial | Q44616594 | ||
| The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. | Q45049292 | ||
| Neuroprotection in Huntington's disease: a 2-year study on minocycline | Q45108539 | ||
| Creatine supplementation lowers brain glutamate levels in Huntington's disease | Q45239341 | ||
| George Huntington and hereditary chorea | Q45288544 | ||
| Trial of d-alpha-tocopherol in Huntington's disease | Q45291405 | ||
| Assessment of coenzyme Q10 tolerability in Huntington's disease | Q45292398 | ||
| High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. | Q45296832 | ||
| Riluzole therapy in Huntington's disease (HD). | Q45297539 | ||
| Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial | Q45297817 | ||
| CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease | Q45298950 | ||
| Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease | Q45299926 | ||
| Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results | Q45300364 | ||
| Motor and cognitive improvements in patients with Huntington's disease after neural transplantation | Q45301920 | ||
| A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease | Q45303631 | ||
| Bilateral human fetal striatal transplantation in Huntington's disease. | Q45305502 | ||
| Riluzole in Huntington's disease: a 3-year, randomized controlled study | Q45305925 | ||
| Unified Huntington's disease rating scale: Reliability and consistency | Q57422462 | ||
| Vitamin E in treatment of Huntington's chorea | Q66839991 | ||
| P921 | main subject | Huntington's disease | Q190564 |
| P577 | publication date | 2009-07-08 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Therapeutic interventions for disease progression in Huntington's disease |
| Q27335053 | A new drug design targeting the adenosinergic system for Huntington's disease |
| Q22305812 | Advances in the Pharmacological Management of Huntingtonʼs Disease |
| Q57178432 | Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects |
| Q52311573 | Agreement between clinician-rated versus patient-reported outcomes in Huntington disease |
| Q35106341 | Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year |
| Q37627670 | Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias |
| Q54917713 | Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum. |
| Q36773397 | Cognitive Impairment in Huntington Disease: Diagnosis and Treatment |
| Q38332316 | Diagnosis and treatment of chorea syndromes |
| Q37386063 | Early Detection of Huntington Disease |
| Q37034726 | Huntington's Disease: The Most Curable Incurable Brain Disorder? |
| Q35140660 | Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies |
| Q27004209 | Modeling Huntington's disease with induced pluripotent stem cells |
| Q38163877 | Neuroprotective effects of psychotropic drugs in Huntington's disease |
| Q55020670 | Population-specific genetic modification of Huntington's disease in Venezuela. |
| Q52685691 | Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease |
| Q42143817 | Recent advances in the management of choreas |
| Q30475466 | Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice |
| Q92583579 | Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort |
| Q37682680 | Targeting glial cells to elucidate the pathogenesis of Huntington's disease. |
| Q35597607 | The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review |
| Q26764930 | The P42 peptide and Peptide-based therapies for Huntington's disease |
| Q22306292 | The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease |
| Q45304275 | Therapies targeting DNA and RNA in Huntington's disease |
| Q38006434 | Therapy in Huntington’s Disease: Where Are We? |
Search more.